86-LB: Real-World Effectiveness of Oral Semaglutide (OS) from a U.S. Commercially Insured and Medicare Advantage Population

Shivappa, Nitin; Swift, Caroline; Noone, JM; Du, Simo; Radin, Michael; Gamble, Cory; Tan, Hiangkiat; Willey, Vincent J.

doi:10.2337/db21-86-lb

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with these data from the pivotal trials, preliminary evidence from studies of early adoption of oral semaglutide in the US also suggests real-world improvements in glycemic control, with a mean HbA 1c reduction of 0.9% observed across patients [85,86]. The PIONEER REAL prospective study is currently enrolling patients as part of local clinical practice in Canada, Europe, and Japan [87][88][89][90][91][92][93].…”

Section: Other Outcomes Of the Global Phase III Trialsmentioning

confidence: 54%

A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes

Aroda

Blonde

Pratley

2022

Rev Endocr Metab Disord

View full text Add to dashboard Cite

Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) were first introduced for the treatment of type 2 diabetes (T2D) in 2005. Despite the high efficacy and other benefits of GLP-1RAs, their uptake was initially limited by the fact that they could only be administered by injection. Semaglutide is a human GLP-1 analog that has been shown to significantly improve glycemic control and reduce body weight, in addition to improving cardiovascular outcomes, in patients with T2D. First approved as a once-weekly subcutaneous injection, semaglutide was considered an ideal peptide candidate for oral delivery with a permeation enhancer on account of its low molecular weight, long half-life, and high potency. An oral formulation of semaglutide was therefore developed by co-formulating semaglutide with sodium N-(8-[2-hydroxybenzoyl]amino)caprylate, a well-characterized transcellular permeation enhancer, to produce the first orally administered GLP-1RA. Pharmacokinetic analysis showed that stable steady-state concentrations could be achieved with once-daily dosing owing to the long half-life of oral semaglutide. Upper gastrointestinal disease and renal and hepatic impairment did not affect the pharmacokinetic profile. In the phase III PIONEER clinical trial program, oral semaglutide was shown to reduce glycated hemoglobin and body weight compared with placebo and active comparators in patients with T2D, with no new safety signals reported. Cardiovascular efficacy and safety are currently being assessed in a dedicated outcomes trial. The development of an oral GLP-1RA represents a significant milestone in the management of T2D, providing an additional efficacious treatment option for patients.

show abstract

Section: Other Outcomes Of the Global Phase III Trialsmentioning

confidence: 54%

A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes

Aroda

Blonde

Pratley

2022

Rev Endocr Metab Disord

View full text Add to dashboard Cite

show abstract

Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients

Saraiva

Franco

2021

Cardiovasc Diabetol

View full text Add to dashboard Cite

Cardiovascular events related to atherosclerosis are responsible for high morbidity and mortality among patients with type 2 diabetes. Improvement in care, especially in early stages, is crucial. Oral semaglutide, a glucagon-like peptide 1 analogue, controls blood glucose and results in significant body weight loss in patients with type 2 diabetes. Beyond these well-known effects, an interesting aspect of this drug is its antiatherogenic activity, which should be further explored in clinical practice. This paper reviews the evidence related to oral semaglutide decreasing cardiovascular risk in patients with type 2 diabetes, focusing on the drug’s antiatherosclerotic properties. The glucagon-like peptide 1 analogue restores endothelial dysfunction, induces vasodilatation, and reduces plasma lipids. Oral semaglutide showed cardiovascular safety profile, with significant reduced risk of death from cardiovascular events. Based on current data, clinicians should consider oral semaglutide for type 2 diabetes management.

show abstract

86-LB: Real-World Effectiveness of Oral Semaglutide (OS) from a U.S. Commercially Insured and Medicare Advantage Population

Cited by 2 publications

References 0 publications

A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes

A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes

Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients

Contact Info

Product

Resources

About